Premium
A comparison study of prabotulinumtoxinA vs onabotulinumtoxinA in myostatin‐deficient mice with muscle hypertrophy
Author(s) -
Bak Dongho,
Choi Mi Ji,
Lee Esther,
Kwon TaeRin,
Kim Jong Hwan,
Nam SangHyun,
Kim KyoungYun,
Ahn Seung Won,
Mun SeogKyun,
Na Jungtae,
Kim Beom Joon
Publication year - 2019
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.13151
Subject(s) - myostatin , muscle hypertrophy , denervation , sciatic nerve , medicine , hindlimb , endocrinology , haematoxylin , skeletal muscle , muscle atrophy , atrophy , neuromuscular junction , acetylcholine , chemistry , biology , immunohistochemistry , neuroscience
Botulinum toxin A (Bo NT ‐A) is used clinically for various muscle disorders and acts by preventing the release of the neurotransmitter acetylcholine into the synapse space. Here, we compared the efficacy of prabotulinumtoxinA ( PRA ) and onabotulinumtoxinA ( ONA ) for the reduction in hypertrophy in myostatin‐deficient ( Mstn −/− ) mice. Two different Bo NT ‐A products (2.5, 10 and 25 U/kg) were injected to paralyse the hindlimb for 2 months, after which sciatic nerve conduction study, 3D micro‐ CT , haematoxylin and eosin (H&E) and dystrophin staining were conducted. Administration of Bo NT ‐A products induced denervation‐mediated atrophy and alleviated muscle hypertrophy generated in Mstn −/− mice. The present study revealed that each Bo NT ‐A regulates skeletal muscle size, myofibre number and myofibre diameter in Mstn −/− mice. The potential applicability of Bo NT ‐A for the treatment of rare muscle hypertrophic diseases was demonstrated. Compared with ONA , PRA had a comparable ability to act in the local area.